GlassScriptPhysician profile
Philip A Adelman
NPI 1376594630
$10,120.24
in general payments reported to CMS, 2019-2025
53 companies · $2,382 in 2025
The $2,382 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,726 · 2020: $1,331 · 2021: $910 · 2022: $998 · 2023: $724 · 2024: $1,049 · 2025: $2,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,004.81 |
| Education | $150.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,194.58 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $777.06 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $766.75 | 2019-2025 | Nayzilam, Rystiggo, Zilbrysq |
| Supernus Pharmaceuticals, INC. | $744.30 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $722.19 | 2020-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $655.15 | 2019-2025 | |
| Biogen, INC. | $575.62 | 2019-2025 | Vumerity, Tysabri |
| Tg Therapeutics, INC. | $410.19 | 2023-2025 | |
| Lilly USA, LLC | $376.01 | 2019-2025 | Kisunla, Amyvid |
| Genzyme Corporation | $325.20 | 2019-2021 | |
| Sk Life Science, INC. | $252.76 | 2022-2025 | Xcopri |
| Neurelis, INC. | $243.57 | 2021-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $223.33 | 2019-2025 | Crexont, Ongentys, Rytary |
| Acadia Pharmaceuticals INC | $220.37 | 2019-2024 | Nuplazid |
| Pfizer INC. | $219.77 | 2023-2025 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Adelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.